Business
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymi
About this update from Upstream Bio, Inc.
[{"type":"image","alt":"Upstream Bio","displaySize":"","headline":null,"caption":"Upstream Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/7eec5fc82ac1c0c7b44a43354897946b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H5BTQQnQ0o0LKqeNgUfTeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/7eec5fc82ac1c0c7b44a43354897946b","width":300,"height":300}},"lazy":false},{"type":"text","content":"WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in participants with CRSwNP and comorbid asthma, as well as its impact on nasal and blood biomarkers.","length":802,"tagName":"p"},{"type":"text","content":"Presentation details:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Presentation Title: Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, Administered in Participants with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma in the VIBRANT TrialPresenting Author: Joseph K. Han, MD, Old Dominion UniversityPoster Board Number: P1397Session: B32 – Rise of the Biologics: A New Hope for Breathing EasierPresentation Date and Time: Monday, May 18, 2026 – 11:30 AM – 1:15 PM ET","length":430,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":430,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Presentation Title: Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, in Chronic Rhinosinusitis with Nasal Polyps: Effect on Type 2 Inflammatory Biomarkers in the VIBRANT TrialPresenting Author: Joseph K. Han, MD, Old Dominion UniversityPoster Board Number: P1398Session: B32 – Rise of the Biologics: A...